Literature DB >> 30590558

The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy.

Steven C Lin1, Alex Goldowsky2, Konstantinos Papamichael1, Adam S Cheifetz1.   

Abstract

As patients with inflammatory bowel disease (IBD) are living longer and our medical armamentarium expands, gastroenterologists are more frequently faced with treatment decisions about patients with IBD who also have a history of malignancy. This review aims to summarize the current literature on IBD, the inherent risk of developing gastrointestinal and extra-intestinal malignancies, and the risk of malignancies associated with available biologic and immunomodulatory therapies and to discuss the overall treatment strategy for a patient with a history of malignancy.
© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adverse events; biologic therapy; cancer; immunomodulators; lymphoma; melanoma; nonmelanoma

Mesh:

Substances:

Year:  2019        PMID: 30590558     DOI: 10.1093/ibd/izy376

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  2 in total

Review 1.  The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.

Authors:  Jessica Kimmel; Jordan Axelrad
Journal:  Curr Gastroenterol Rep       Date:  2020-02-13

2.  The Recurrence of Cervical Precancerous Lesion Among HIV Positive and Negative Ethiopian Women After Cryotherapy: A Retrospective Cohort Study.

Authors:  Agajie Likie Bogale; Tilahun Teklehaymanot; Jemal Haidar Ali; Getnet Mitike Kassie; Girmay Medhin
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.